Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
Alongside the development of an ever-increasing number of cancer therapies available for patients, cancer survivorship has steadily increased over the past three decades, and the impact on patients has been significant.1 However, with new therapies, comes new challenges, and the management of cancer therapy-related cardiovascular toxicity (CTR-CVT) has become an important consideration for healthcare professionals.2
Chronic Lymphocytic Leukemia (CLL)
Managing cumulative cardiovascular toxicity associated with BTK inhibitors
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA
Continuous BTK inhibitors in CLL treatment: benefits and drawbacks
Kerry Rogers, MD, The Ohio State University, Columbus, OH
Real-world incidence of ibrutinib-related cardiotoxicity in CLL
Lee Greenberger, PhD
Leukemia & Lymphoma Society, New York, NY
Lymphoma
Cardiovascular outcomes of patients with FL & DLBCL treated with doxorubicin-based chemotherapy
Vincent Camus, MD, University of Rouen, Rouen, France
MAGNOLIA: zanubrutinib in patients with R/R marginal zone lymphoma
Kim Linton, MBChB, MRCP, PhD, FRCP, The Christie NHS Foundation Trust, Manchester, UK
Amyloidosis
CHIP in patients with AL amyloidosis: clinical implications
Paolo Lopedote, MD, St Elizabeth’s Medical Center, Boston, MA
The importance of the MDT to provide adequate treatment and care to patients with amyloidosis
Paolo Milani, MD, PhD, Amyloidosis Research and Treatment Center, Pavia, Italy
Acute Myeloid Leukemia (AML) & Myelodysplastic Syndromes (MDS)
Cardiotoxicity of CPX-351 vs 7+3 chemotherapy in AML
Jorge Cortes, MD, Augusta University, Augusta, GA
Clonal hematopoiesis in AML & insights into a novel CHIP risk stratification score
Benjamin Ebert, MD, PhD, Dana-Farber Cancer Institute, Boston, MA
MCL-1 inhibition with AZD5991 in R/R hematologic malignancies
Pinkal Desai, MD, MPH, Weill Cornell Medical College, New York City, NY
Sources
- Vaz-Luis I, et al. ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe. Ann Oncol 2022;33:1119–33.
- Lyon A, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging 2022;23:e333–e465.
Glossary
AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CTR-CVT, cancer-therapy cardiovascular-related toxicity; MDS, myelodysplastic syndromes.
This educational activity has received independent medical education support from Johnson & Johnson. This supporter has no influence over the production of the content.
